Clinical Trial Phases Explained: Phase 1 vs Phase 2 vs Phase 3 vs Phase 4

Drug development moves through four distinct phases, each answering a specific question about safety, dosing, efficacy, and long-term effects. The phase determines who can participate, what risks are involved, what compensation (if any) is offered, and what the study is trying to prove. Understanding clinical trial phases helps potential participants make informed decisions about whether – and which – trial to join, and helps patients awaiting new treatments understand where a drug sits in the development pipeline. This guide breaks down each phase with realistic expectations on size, duration, and what participants actually experience. It is educational only; decisions about joining a study should be made with the study team and your own doctor.

Phase 1 – first testing in humans

Phase 1 is the first step where a drug or treatment moves from laboratory and animal studies into people. The primary goal is safety and dosing, not efficacy. Researchers want to identify side effects, find a tolerable dose range, and understand how the drug is absorbed, distributed, metabolized, and excreted (pharmacokinetics).

• Typical size: 20-100 participants
• Duration: several months, sometimes longer
• Participants: often healthy volunteers, sometimes patients with the target condition (especially in oncology)
• Compensation: often $1,000-$7,000 for healthy-volunteer studies (frequently involving inpatient stays); amounts vary by study

Phase 1 carries the most uncertainty because the drug has limited prior human exposure. Doses often start very low and escalate gradually. Studies are typically run at specialized clinical research units with intensive monitoring. Per the FDA, roughly 70% of drugs successfully move from Phase 1 to Phase 2. The FDA’s drug development overview details the regulatory framework, including the review process that protects volunteers from unreasonable and significant risk.

Phase 2 – early efficacy in the target population

Phase 2 tests the drug in patients with the target condition, often for the first time. The goal is to learn whether the drug works at all and to refine the dosing. Researchers compare doses, gauge the size of the effect, and keep monitoring safety in a larger, more vulnerable patient group.

• Typical size: up to several hundred patients with the target condition
• Duration: several months to 2 years
• Participants: patients with the specific condition being treated
• Compensation: typically modest per-visit payments for time and travel (varies by study)

Phase 2 is where most drug candidates fail. According to the FDA, only about 33% of drugs advance from Phase 2 to Phase 3 – meaning roughly two-thirds do not. The trial is large enough to detect efficacy signals but not large enough to prove definitively that a drug works. Encouraging Phase 2 results typically trigger a meeting with the FDA to design the Phase 3 program.

Phase 3 – pivotal efficacy and safety

Phase 3 is the largest and most rigorous phase, designed to confirm that the drug works and to characterize its safety in a large population. These are the trials that generate the core data the FDA reviews for marketing approval.

• Typical size: about 300-3,000 patients across multiple sites
• Duration: 1-4 years
• Participants: a broader patient population with the target condition
• Compensation: similar to Phase 2, modest per-visit amounts

Phase 3 trials are typically randomized, double-blind, and placebo- or active-comparator-controlled, producing statistically powered comparisons that can change medical practice. Even at this stage, success is far from guaranteed: the FDA notes that only about 25-30% of drugs in Phase 3 move forward. A trial may show inadequate efficacy, unacceptable safety, or commercial considerations that don’t justify continued development.

Phase 4 – post-marketing surveillance

Phase 4 happens after FDA approval, once the drug is on the market. The goal is to characterize long-term safety, rare side effects that didn’t surface earlier, real-world effectiveness, and use in populations not heavily studied during development.

• Typical size: often several thousand patients, sometimes far more
• Duration: years to decades
• Participants: patients prescribed the drug as part of their normal care
• Compensation: usually none, since the drug is part of standard treatment

Phase 4 is sometimes a formal study (a post-marketing requirement from the FDA) and sometimes observational research using insurance claims and electronic health records. Major safety findings occasionally emerge in Phase 4 that lead to label updates, new warnings, or, in rare cases, drug withdrawal.

Your rights as a participant: informed consent

Joining any clinical trial is voluntary, and it rests on informed consent. Before you enroll, the study team must explain the trial’s purpose, what will happen, how long it lasts, the known and possible risks, any potential benefits, and the alternatives – including the option not to participate. Informed consent is an ongoing process, not just a signature: the team should keep you updated as new information emerges. Registered studies are reviewed by an institutional review board (IRB) or ethics committee charged with protecting participants, and the FDA can halt a study that exposes people to unreasonable risk.

Two points are worth emphasizing. First, you have the right to leave a trial at any time, for any reason, without penalty to your regular medical care. Second, a clinical trial is research, not guaranteed treatment – it may or may not help you, and some studies assign participants to a placebo (an inactive comparison) or use randomization so that neither you nor sometimes the researchers know which group you’re in. Ask the team how these apply to the specific study, and confirm details on ClinicalTrials.gov. When in doubt, verify current specifics with the study team.

How participants experience each phase

Phase 1 is the most intensive from a participant’s perspective. Healthy-volunteer studies often involve multi-day inpatient stays at clinical research units, frequent blood draws, and close monitoring – the compensation reflects that intensity. Patient-focused Phase 1 trials (especially in oncology) usually involve outpatient visits with extensive monitoring.

Phase 2 and 3 trials feel more like enhanced medical visits. Participants typically come in every 2-4 weeks during the active treatment period. Visits include vital signs, lab work, questionnaires, sometimes imaging, plus the study drug if applicable. The schedule is structured but generally compatible with normal life.

Phase 4 trials, when conducted formally, are usually the lightest touch. Many are observational – researchers track outcomes without changing patient care. Participants often don’t experience a Phase 4 study as a “trial” beyond signing consent forms and allowing their data to be collected.

Risk levels by phase

Risk is highest in Phase 1 (least human safety data) and lowest in Phase 4 (drug already approved and widely used). Phase 1 healthy-volunteer trials have, on rare occasions, produced serious adverse events – including deaths – when novel drugs affected human biology in ways the preclinical data did not predict. The TGN1412 trial in 2006 and the BIA 10-2474 trial in 2016 are the most cited examples, and both led to stronger safeguards for first-in-human studies.

Phase 2 and 3 trials test drugs that have already cleared earlier human safety testing, so the absolute risk is lower – though risks specific to each individual remain, since the drug is still investigational. Phase 4 risk is similar to taking the approved drug as prescribed, often with the added benefit of extra monitoring.

What phase a drug is in matters for patients

For patients with serious or rare conditions, the phase of available trials affects both access and risk. Phase 1 oncology trials, for instance, often enroll patients with advanced disease who have exhausted standard treatments – a very different risk-benefit calculation from healthy-volunteer Phase 1 studies. Phase 2 and 3 trials offer access to treatments that have already shown some safety and efficacy signals, but nothing is guaranteed.

For specific conditions, our guides to clinical trials for breast cancer, clinical trials for Alzheimer’s, and other conditions cover what trials are typically active and what phases they tend to be in. For broader context, see our medical conditions guide. Whatever the condition, discuss any trial with your own doctor, who can weigh it against your overall care.

Frequently Asked Questions

Which phase is safest for participants?

Phase 4, because the drug is already FDA-approved and has extensive human safety data. Phase 1 carries the most uncertainty, since the drug is being tested in humans for the first time. Every phase, though, includes protections such as informed consent and ethics review.

Are Phase 1 trials only for healthy people?

No. Phase 1 oncology trials typically enroll patients with advanced cancer rather than healthy volunteers, because the risk-benefit balance differs when standard options are exhausted. For many other conditions, Phase 1 uses healthy volunteers.

Can I leave a clinical trial after I join?

Yes. Participation is voluntary, and you can withdraw at any time, for any reason, without losing access to your regular medical care. Tell the study team if you’re considering leaving so they can do any recommended safety follow-up.

How do I know what phase a trial is in?

ClinicalTrials.gov lists the phase for every registered trial, along with eligibility criteria and contact information. The phase is also explained during the informed consent process, and sponsors are expected to provide this information clearly.

Do all drugs go through all four phases?

Most prescription drugs do, though Phase 4 may be voluntary or required depending on the drug. Some drugs receive accelerated approval based on Phase 2 data, with Phase 3 conducted after approval as a confirmatory study.

How much do participants get paid?

Amounts vary widely. Phase 1 healthy-volunteer studies may pay in the low thousands of dollars for a significant time commitment, often including inpatient stays; Phase 2 and 3 trials usually offer modest per-visit payments; and Phase 4 studies typically don’t pay, since the drug is part of standard care. See our clinical trial compensation guide for detail.

The bottom line on clinical trial phases

The four-phase system is designed to balance the need for evidence with participant safety. Each phase answers specific questions: Phase 1 establishes safety and dosing, Phase 2 demonstrates early efficacy, Phase 3 provides pivotal evidence of effectiveness, and Phase 4 monitors real-world outcomes. Participants face different risks, time commitments, and compensation at each phase – and, at every phase, the protections of informed consent and the right to withdraw. Understanding which phase a study is in, and talking it through with your own doctor, is one of the most important steps in deciding whether to enroll.

Sources

• U.S. Food and Drug Administration (FDA), Step 3: Clinical Research
• ClinicalTrials.gov (National Library of Medicine), Learn About Studies
• National Institutes of Health / National Institute on Aging, What Are Clinical Trials and Studies?